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Abstract: Liposomes have long been effective delivery vehicles for transport of toxins to 
peripheral  cancers.  The  combination  of  convection-enhanced  delivery  (CED)  with 
liposomal  toxins  was  originally  proposed  to  circumvent  the  limited  delivery  of 
intravascular liposomes to the central nervous system (CNS) due to the blood-brain-barrier 
(BBB). CED offers markedly improved distribution of infused therapeutics within the CNS 
compared  to  direct  injection  or  via  drug  eluting  polymers,  both  of  which  depend  on 
diffusion  for  parenchymal  distribution.  This  review  examines  the  basis  for  improved 
delivery  of  liposomal  toxins  via  CED  within  the  CNS,  and  discusses  preclinical  and 
clinical  experience  with  these  therapeutic  techniques.  How  CED  and  liposomal 
technologies may influence future neurooncologic treatments are also considered. 
Keywords:  blood-brain-barrier;  convection-enhanced  delivery;  diffusion;  glioma; 
liposome; neurooncology 
 
1. Introduction  
The effective delivery of therapeutic agents via the vasculature to the central nervous system (CNS) 
is significantly affected by the presence of the blood-brain-barrier (BBB) [1]. The endothelial cells of 
the BBB differ from those in other vascular locations, since they lack fenestrations and have more 
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extensive tight junctions (TJs), while lacking significant pinocytic vesicular transport [2]. In addition, 
the BBB features an acellular basement membrane immediately beneath the endothelial cells, and two 
other cellular components, the pericytes and astrocytes encompassing and completing this limiting 
structure to ingress into the CNS [2]. While the TJs significantly reduce the paracellular passage of 
hydrophilic molecules into the brain [3], O2, CO2, and small lipophilic molecules easily diffuse across 
the cell membranes, driven by their concentration gradients [4]. Specific membrane transporters are 
available for the uptake of glucose and amino acids from the blood, while many macromolecules are 
taken up via receptor-mediated endocytosis [5–7]. All of these components, working in concert, are 
essential to the homeostasis of the CNS provided in part by the BBB. 
In neurooncology, the BBB is often disrupted in association with the intrinsic growth of tumors within 
the CNS parenchyma [8,9]. While some feel that the BBB does not play a significant role in ―impeding the 
success of brain  tumor chemotherapy‖ [10–12], most feel that the  presence of the BBB  significantly 
reduces  the  effective  delivery  of  intravascular  chemotherapeutic  agents  to  the  brain  [13].  The  major 
strategies developed to improve chemotherapeutic delivery to brain tumors involve designing drugs or 
methods  with  improved  permeability  to  the  BBB  [14–16],  delivery  strategies  that  feature  BBB  
disruption  [17–19],  or  by  circumventing  the  BBB  altogether  by  intrathecal  cerebrospinal  fluid  (CSF) 
delivery  [20–23], or intraparenchymal  delivery  that excludes convection enhanced delivery (CED)  
methods [24–29]. All of these approaches attempt to achieve turmoricidal drug levels and increased contact 
time within, and in proximity to, the brain tumor, and thereby provide effective treatment [13,30]. 
Over  the  last  10–15  years,  local  drug  delivery,  bypassing  the  BBB,  has  gained  momentum  by 
offering expanded capabilities to the magnitude and types of drugs that can be delivered within CNS 
for  the  treatment  of  neurooncologic  pathologies  [31],  and  by  delivering  therapeutic  levels  of 
chemotherapeutic agents within brain parenchyma compared to other delivery modalities [30]. The 
remainder of this review directs attention to two particularly appealing delivery modalities for use with 
neurooncologic  chemotherapeutic  agents,  CED  and  liposomes.  Although  developed  independently, 
these  two  delivery  options  have  been  recently  combined  in  an  effort  to  improve  efficacy  in  the 
treatment of CNS malignancies. Details of both modalities will be explored and their future prospects 
in neurooncology considered. 
2. Diffusion versus Convection-Enhanced Delivery (CED) 
To better understand the basic physiology and distribution mechanisms associated with CED, it is 
important  to  contrast  it  with  diffusion.  Diffusion-based  delivery  mechanisms  are  essential  to  the 
distribution of chemotherapeutic agents within the brain parenchyma following intravascular delivery, 
intrathecal cerebrospinal fluid infusions, direct brain injections, elution from implanted polymers, and 
via  microdialysis  (Figure  1A).  With  all  of  these  distribution  options,  therapeutic  agents  disperse 
through  the  extracellular  space  (ECS)  according  to  their  concentration  gradient  and  inversely 
proportional  to  their  molecular  size  [32–34].  Chemotherapeutic  agent  diffusion  does  not  typically 
extend for greater than a few millimeters from the site of greatest concentration with the modalities 
listed above [35], and, especially for smaller molecules, can be impacted by capillary clearance and 
metabolism [36–38], affecting the local ECS microenvironment. To date, delivery of chemotherapeutic 
agents  utilizing  these  diffusion-based  technologies  are  exceedingly  difficult  to  standardize  and  Toxins 2011, 3                      
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control  [39].  Diffusion,  unfortunately,  provides  a  limited  and  heterogeneous  distribution  of 
therapeutics in the normal brain ECS [40], and that associated with gliomas [41,42], due in part to its 
mechanism of action and intrinsic parenchymal factors [39–43].  
Figure  1.  (A)  Diffusion-based  delivery  system.  A  characteristically  larger  injection 
cannula is used to deliver the infusion volume within the target region for direct injection 
and microdialysis. The infusion volume typically displaces the surrounding parenchyma at 
the  tip  of  the  cannula  and  forms  a  small  cavity  from  which  diffusion  occurs  into  the 
surrounding  brain,  eventually  expanding  to  the  diffusion  limit,  but  falling  far  short  of 
filling the subcortical target volume. Implanted polymers filling the infusion volume show 
similar diffusion volume. Another factor that limits the effectiveness of this technique is 
the development of backflow or reflux (dashed black arrow) of the infusate out of the target 
region, along the path of the injection cannula. This is seen most often with larger cannulae; 
(B)  Convection-enhanced  delivery  system.  Optimal  CED  cannulae  are  narrow  
(~165 µm) and are attached to the pump mechanism that controls the rate of infusion. The 
infusion cannula extends for a distance beyond the outer guide cannula, with the transition 
between the two called the cannula step. The infusate is delivered with a constant flow rate 
(most commonly 0.2–5.0 µL/min) from the infusion cannula tip. This flow rate establishes 
a pressurized extracellular bulk flow that allows the homogenous distribution of various 
sized  molecules/particles  significant  distances  from  the  infusion  cannula  tip.  Reflux 
(dashed black arrow) typically only occurs up to the cannula step, and major backflow 
along the cannula and out of the target region prevented by central placement of the step 
within the target volume. The convection limit can more easily approach the subcortical 
target volume limit.  
 Toxins 2011, 3                      
 
 
372 
In contrast to diffusion, CED is a delivery modality within the brain ECS that utilizes bulk flow, or 
fluid convection, established as a result of a pressure gradient [44], rather than a concentration gradient 
(Figure 1B). Through the maintenance of a pressure gradient from the delivery cannula tip to the 
surrounding tissues, CED is able to distribute small and large molecules, including high molecular 
weight proteins, to clinically significant target volumes [44,45], centimeters rather than millimeters in 
diameter. Viruses and other large particles [46], including liposomes [47], are also easily distributed 
within the brain via CED. The advantages of CED over diffusion, therefore, include: (i) expanded 
volume of distribution (Vd); (ii) a more uniform concentration of the infused therapeutic within the 
target Vd; (iii) delivery of the vast majority of the infused therapeutic within the target volume [45].  
Our understanding of CED distribution has been amplified by the realization that arterial pulsations 
within the brain’s perivascular spaces enhances the distribution of convected therapeutics [48], and by 
a  better  appreciation  of  the  complexities  of  the  extracellular  matrix  and  its  effects  on  
convection [49–51], and consideration of the biophysical properties of the ECS volume fraction [43]. 
Technical CED infusion parameters, such as cannula size and shape (Figure 2), infusion rate (usually 
0.2–5.0 µL/min or 0.012–0.3 mL/h), infusate concentration, and tissue sealing time, have been defined 
and refined to improve distribution of therapeutics [46,52–54], while limiting potential toxicities and 
morbidities  [46,54,55].  A  major  advance  in  the  safe  and  efficacious  use  of  CED  in  clinical 
neurosurgery  has  been  the  development  of  real-time  convective  delivery  (RCD)  [56–58],  which 
currently utilizes magnetic resonance (MR) imaging to visualize the CED process with the aid of  
co-convected contrast agents (Figure 2) [55,59–61]. The use of RCD has become critical in allowing 
treating physicians to directly monitor the distribution of therapeutics within the brain. Reflux along 
the CED catheter or leakage outside the target area, especially at higher flow rates, can be monitored 
and corrective steps taken, such as retargeting the catheter or altering the rate of infusion [39,62].  
Several recent human clinical trials that utilized CED for the delivery of therapeutics to the brain 
without RCD have been regarded as not meeting clinical endpoints, including trials for treatment of 
neurodegenerative disease [63–66], and neoplastic conditions [67–73]. It remains unclear as to whether 
the inconclusive results in these trials could be: related to lack of efficacy of the therapeutic; due to 
variability in response of patients to the therapeutic; due to lack of consistent volumetric delivery of 
the therapeutic to the target; or, to some additional factor(s) yet to be confirmed. Lack of effective 
monitoring of the infused therapeutics, without imaging, and the likelihood of poor drug distribution in 
these human trials has led to recurring criticisms [74,75].  
Similarly, in the first comparative Phase III trial of CED delivered chemotherapy versus Gliadel wafer 
(diffusion-based  eluting  polymer)  therapy  for  recurrent  glioblastoma  treatment  [75],  no  significant 
survival difference was seen between the two groups. Intrinsic tumor barriers and parenchymal effects 
may  be  the  primary  forces  influencing  the  distribution  of  convected  chemotherapeutic  agents  [76]. 
Phenotypic characteristics associated with glioblastoma multiforme (GBM) include rapid growth, high 
glucose consumption, intra-tumoral necrosis, hypoxia, and vasogenic brain edema [77]. Although greater 
edema should allow facilitated diffusion due to a larger ECS, diffusion appears impeded in tumors due to 
altered  extracellular  matrix  composition  [41].  Tumor  malignancy  grade  strongly  corresponds  to  an 
increase volume of the ECS accompanied by structural changes manifested by increased barriers to 
diffusion for small molecules [41]. Whereas in low-grade tumors the diffusion of molecules is reduced 
mainly by the presence of a dense network of tumor cell processes, the barriers to diffusion within the Toxins 2011, 3                      
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ECS of high-grade gliomas is caused by the overproduction of certain glycoprotein components of the 
extracellular matrix (ECM), mainly tenascin [42,78]. ECM glycoproteins not only stabilize the ECS 
volume, but also serve as a substrate for adhesion and subsequent migration of the tumor cells through 
the  enlarged  ECS.  These  same  alterations  in  ECS  structure  may  hinder  the  diffusion  of  certain 
neuroactive substances or therapeutic molecules within neoplastic tissue [78]. These barriers to diffusion 
and convection, directly related to the tumor parenchyma, provide a less permeable medium for CED, 
and even less so for diffusion-based delivery options. 
Figure  2.  (A) Photograph of actual step  cannula used for CED.  The  guide  cannula is 
stereotactically placed within brain tissue to just above the intended target. The delivery 
cannula is then passed through the guide to reach the final target point. (B-D) Coronal MR 
images of RCD using mixture of gadolinium liposomes and liposomes carrying CPT-11 in 
a canine with temporal lobe glioma (outlined by white arrowheads); (B) Pre-CED image 
following  catheter  placement  within  tumor  mass.  Notice  ventricular  mass  effect  on 
ipsilateral ventricle (outlined in white); (C) RCD with significant filling of tumor volume 
with contrast. Note contrast reflux along guide cannula (small white arrows) and increased 
mass effect on ventricle; (D) Coronal MRI one month after CPT-11 RCD. Notice decrease 
in mass effect on ipsilateral ventricle and temporal lobe in this canine patient. 
 
 
   Toxins 2011, 3                      
 
 
374 
While  interstitial  fluid  velocity  measurements  in  vivo  are  difficult  to  assess,  investigators  have 
developed mathematical models based on physical principles to predict fluid transport that occurs 
during CED in normal and neoplastic brain tissue [79,80]. These models predict that the tumor core 
maintains  an  elevated  interstitial  fluid  pressure  [79],  and  that  tumors  have  an  outward  flow  of 
extracellular fluid (ECF) at their periphery [80]. For CED to adequately perfuse a neoplasm, therefore, 
this pressurized outward flow of ECF from the tumor core must be overcome, unless the delivery 
catheter is somehow centered in the lesion’s center of pressure [76]. Despite adequate coverage of a 
tumor  volume with  an  effective therapeutic via CED, the rapid  clearance  of the drug due  to this 
outward  flow  of  ECF  (and  reduced  concentration-time  product)  may  provide  little  or  no  clinical 
efficacy [76,81]. Such interstitial pressures and fluid flows make it even less likely that peripherally 
placed  diffusion-based  therapeutics  will  influence  the  tumor  core.  The  use  of  RCD  in  future 
neurooncologic  and  neurodegenerative  disease  trials  may  allow  better  differentiation  of  efficacy 
between CED and diffusion-based treatment modalities, but will also allow direct visualization of the 
Vd  of  convection  therapies,  and  allow  a  better  estimation  and  standardization  of  the  therapeutic  
contact time.  
3. Liposomes 
Liposomes have been included into a group of phospholipid nanoparticles, that form a ―core-shell 
structure‖ [82–84], since their initial description by Bangham [85–87], and which can be used to carry 
various  therapeutic  agents.  Liposomes  are  typically  composed  of  double  chain  phospholipid 
amphiphiles  (chemical  compounds  with  combined  hydrophilic  and  lipophilic  properties)  in 
combination  with  cholesterol,  forming  spheroidal  bilayer  membrane  structures  that  encompass  an 
aqueous internal domain [83,88] (Figure 3). The length of the fatty acid chains and the presence or 
absence  of  double  bonds  within  the  bilayer  lipids  affects  the  membrane  fluidity,  as  does  the 
combination  of  different  phospholipids  within  the  membrane  structure  [89,90].  The  cholesterol 
strengthens  and  stabilizes  the  bilayer  membrane  [91],  and  reduces  cation  leakage  in  physiologic 
systems [92]. Increasing the molar cholesterol content of liposomal drug carriers reduces the release 
kinetics  of  the  therapeutic  [93].  Specific  liposomal  properties,  therefore,  can  be  tailored  by  the 
membrane  component  makeup  [94,95],  and  most  recently  through  the  combination  of  polymer 
nanoparticle technology with liposomes [96].  
Liposomes are typically formed by the addition of energy to amphipathic phospholipids in aqueous 
solution. Liposomal structures can range from long tubules to spheres, with dimensions from several 
hundred Angstroms to fractions of a millimeter [97]. A prototypical liposomal vesicle has a single, 
closed lipid bilayer confining a single internal aqueous volume. The three basic types of liposomal 
structures include multilamellar vesicles (MLV, typically > 500 nanometers (nm)), small unilamellar 
vesicles  (SUV,  <100  nm),  and  large  unilamellar  vesicles  (LUV,  ≥100  nm)  [94,97,98]  (Figure  4). 
Sonication  of  phospholipids  in  an  aqueous  solution  can  produce  liposomes  [97],  but  in  extreme 
circumstances can damage the vesicles. Low shear conditions favor the development of MLVs, while 
increasing shear produces LUVs, and finally SUVs. 
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Figure 3. A schematic representation of the phospholipid structure and that of a theoretical 
therapeutic liposome  in  aqueous  solution.  (A)  Phosphatidyl  choline is a typical  double 
chain  amphiphile  with  the  steric  characteristics  that  preferentially  forms  bilayers  and 
liposomes. The hydrophilic head (blue dashed rectangle) of the molecule is charged and 
contains the anionic phosphate group and that cationic choline molecule, attracting water to 
its domain. The glycerol molecule (within black dotted rectangle) connects the hydrophilic 
end of the amphiphile to two fatty acids (typically of different lengths (purple and green 
groups), which make up the hydrophobic tails (yellow dashed rectangle); (B) A schematic 
representation of the phosphatidyl choline amphiphile (or other double chain amphiphile), 
featuring  the  hydrophobic  head  (blue)  and  hydrophilic  tails  (yellow);  (C)  Schematic 
representation  of  a  theoretical  therapeutic  liposome  in  aqueous  solution,  seen  in  cross 
section. The double chain amphiphiles arrange themselves in a spherical bilayer vesicle, 
with water surrounding the outside of the liposome and retained within the central aqueous 
milieu. Cholesterol in the membrane (orange rectangle) stabilizes the liposome structure. 
Complex  targeting  molecules  (green)  are  shown  on  the  outer  surface  of  the  bilayer, 
allowing preferential binding of the liposome to targeted cell surface receptors for cellular 
uptake.  Immune  system-defeating  molecules  (black)  (e.g.,  polyethylene  glycol,  PEG), 
through their enhanced steric effects, increase the ability of the liposome to avoid clearance 
via phagocytosis. Within the phospholipid bilayer (red brackets), lipophilic drugs can be 
assimilated and transported via the liposome. Finally, small and large molecular species 
can exist within the liposome’s aqueous core (based on liposomal size), including proteins, 
drugs, genetic material, viruses, and other particulates, for eventual incorporation within 
the target cell. 
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Figure 4. A size-based, schematic representation of the three basic liposomal structures. 
Black line at bottom of the figure represents 500 µm. A multilamellar vesicle (MLV) has 
layered  membranes  separated  by  minimal  aqueous  volume  and  is  typically  a  larger 
structure  that  provides  an  increased  hydrophobic  volume  for  better  incorporation  of 
lipophilic drugs. A large unilamellar vesicle (LUV) provides increased internal volume for 
incorporation  of  hydrophilic  therapeutics.  A  small  unilamellar  vesicle  (SUV)  is  also 
depicted with an expanded view of the typical component membrane structure shared by all 
three liposomal types.  
 
Regardless of the preparation methodologies [99–111], liposome formation results from the addition 
of  energy  (e.g.,  heating,  sonication,  homogenization,  shaking,  etc.)  altering  the  tendency  for  lipid 
membranes to form a flat bilayer at an aqueous interface, and instead form bilayered vesicles [112]. 
Unfortunately, only a few of the conventional liposomal production methods are capable of entrapping 
large quantities of water-soluble agents [107]. Conventional liposomal production methods, such as  
the reverse-phase evaporation technique [101], ether injection/vaporisation technique [99,100], and  
freeze-thaw method [102], produce a heterogeneous mixture of large unilamellar vesicles (LUV) or 
multilamellar vesicles (MLV) [112]. Production of a more homogenous liposome mixture has been 
accomplished through centrifugation [113], or filtering methods [114,115]. 
Typically, liposomes within the circulation are quickly coated with opsonizing plasma proteins, 
taken up by phagocytic cells within the reticuloendothelial system (RES) (see next section, Cellular 
Uptake of Liposomes), and rapidly cleared from the bloodstream. The addition of polyethylene glycol 
(PEG) or derivatives to the external membrane surface of liposomes (PEGylation) has proven effective 
in inhibiting RES clearance and thereby increasing plasma circulation time [116–118]. The mechanism 
of PEGylated liposome longevity has been investigated [119], and postulated to be primarily due to a 
protective conformational cloud of steric interference on the liposomal surface associated with the 
flexible hydrophilic polymers. Such a protective surface also alters surface charge characteristics, and 
reduces opsonization and phagocytic clearance.  
From the circulating bloodstream, liposomes of small and large diameters are able to diffuse across 
the BBB due to their lipophilic characteristics. SUVs modified with brain transport molecules on their Toxins 2011, 3                      
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surface can also undergo receptor-mediated or absorptive-mediated transcytosis [98]. Within the brain, 
liposomes present little or no toxicity to the host [120], and most commonly enter cells within the CNS 
via endocytosis. Upon entering the CNS ECS, liposomal diffusion is markedly limited due to their size 
and cellular binding characteristics. 
4. Cellular Uptake of Liposomes 
Liposomes  were  first  shown  to  be  effective  intracellular  transport  vehicles  for  substances  that 
typically did not gain access to the intracellular space in 1974 [121]. Two major pathways for cellular 
internalization of liposomes are present: phagocytosis, and endocytosis [122]. Phagocytosis occurs 
primarily  in  professional  phagocytes  (e.g.,  macrophages,  monocytes,  neutrophils,  and  dendritic  
cells) [123]. Fibroblasts, endothelial cells and epithelial cells have some phagocytic capabilities but to 
a  much  lower  extent  [124].  Opsonization  or  tagging  of  the  nanoparticles  for  phagocytosis,  is 
effectively  carried  out  by  serum  proteins,  including  immunoglobulins,  complement  components, 
laminin, fibronectin, C-reactive protein, and type-I collagen [125,126]. Opsonized particles specifically 
attach to phagocytes via receptor-ligand interactions, which trigger a signaling cascade that results in 
actin-dependent  pseudopodia  extension  and  eventual  engulfing  of  the  particle,  ingestion,  and 
processing through phagolysosomes [122]. The entire process can take 30 min to 2 h and is highly 
dependent on surface properties of the ingested particle [123]. Particle size matters in phagocytosis, 
with the process optimized for particles greater than 250 nm, and with smaller particles less efficiently 
internalized  [127].  Larger  sized  liposomes  show  increased  opsonization  by  serum  proteins  and 
phagocytic clearance, a process that has been largely defeated in the peripheral circulation through  
the  use  of  polyethylene  glycol  (PEG)-coating  on  liposomes  [119],  and  other  nanodelivery  
vehicles [122,128]. Additionally, liposomes with a significant surface charge (positive or negative), 
have a much higher binding affinity to phagocytes than vesicles that are neutral, and hydrophobic 
nanoparticles are more readily taken up than hydrophilic non-ionic ones [122]. Finally, shape and 
rigidity  of  the  liposome  or  nanoparticle  also  influence  the  likelihood  of  cellular  uptake  via 
phagocytosis. Less spherical and more rigid particles directly stimulate phagocytic ingestion [122].  
The  uptake  and  intracellular  fate  of  nanoparticles  is  highly  dependent  on  the  above-mentioned 
factors  but  especially  to  particle  size.  Larger  particles  and  volumes  of  the  ECF  are  taken  up  by 
phagocytosis and macropinocytosis through two different mechanisms that share a similar intracellular 
fate  (Figure  5).  Smaller  particles  (<150  nm)  are  taken  up  and  processed  via  at  least  three  other 
mechanisms (Figure 6). Cellular uptake mechanisms for liposomes are summarized in Table 1. 
Non-phagocytic endocytosis is common to all cells and involves uptake of both fluids and solutes 
through four main mechanisms: macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated 
endocytosis, and endocytosis which is independent of clathrin and caveolin [122].  
Macropinocytosis shares some features with phagocytosis and is a clathrin- and caveolin-independent 
cellular  uptake  system  that  occurs  in  macrophages  as  well  as  many  other  cell  types  [129–131]. 
Utilizing membrane protrusions generated by actin interactions in a manner similar to phagocytosis, it 
differs in  the  formation of larger endocytic vesicles  (typically ranging  in  diameter from  1–5  µm) 
through membrane  fusion, which nonspecifically samples  the  ECF  and  its content.  Intracellularly, Toxins 2011, 3                      
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macropinosomes acidify and shrink, sometimes fusing with lysosomes or recycling their contents to 
the cell surface. 
Figure  5.  Schematic  representation  of  intracellular  processing  of  large  liposomal 
nanocarriers (>250 nm diameter) based on phagocytosis and macropinocytosis mechanisms. 
In the phagocytosis pathway (A–E), an MLV (or LUV) is opsonized with serum proteins or 
immunoglobulins  (A).  Receptor  binding  on  the  cell  surface  to  opsonins  results  in  actin 
assembly and particle engulfment (B), leading to the formation of a phagosome (C). With 
maturation of the phagosome, pre-lysosomal vesicles fuse with it and release degradative 
enzymes (D), and finally form a phagolysosome with acidification and degradation of the 
liposomal vesicle and contents (E). In the macropinocytotic internalization pathway (F,G, 
and  E),  large  membrane  protrusions  non-specifically  engulf  a  large  amount  of  ECF, 
including  liposomes  of  various  sizes  (F).  The  fate  of  the  resulting  macropinosome  (G) 
includes processing of its contents via acidification and fusion with enzyme-rich vesicles to 
form  a  phagolysosome  (E).  An  alternative  pathway  (blue  dotted  arrow)  for  the 
macropinosome is to fuse with and recycle its content to the cell surface. 
 
Clathrin-mediated  endocytosis  (CME)  is  essential  to  cellular  homeostasis,  allowing  uptake  of 
signaling  and  nutrient  macromolecules,  and  membrane  components.  Both  receptor-mediated  and  
non-specific  CME  exists,  with  materials  engulfed  ending  up  in  degradative  lysosomes.  CME 
typically  occurs  in  a  membrane  region  enriched  with  the  cytosolic  coat  protein  clathrin,  which 
polymerizes  to  form  a  basket-like  framework  beneath  the  cell  membrane,  causing  invagination 
(clathrin-coated  pit,  up  to  150  nm  in  depth)  and  eventual  dynamin-mediated  formation  of  a  
clathrin-coated vacuole (or vesicle) [132,133], with a diameter of 100 nm [134] to 120 nm [130]. 
The  internalization  of  receptor-ligand  complexes  via  receptor-mediated  CME  is  one  of  the  best 
defined cellular internalization mechanisms  [129], and of paramount importance for various free 
ligands  and  nanocarriers  bearing  targeting  ligands  (e.g.,  LDL,  transferrin,  and  epidermal  growth Toxins 2011, 3                      
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factor),  and  many  viruses  (e.g.,  influenza)  [122,134,135].  Fluid-phase  endocytosis  [134],  or  
receptor-independent CME is an internalization pathway for extracellular fluid and its contents that 
avoids direct binding to the cell membrane components. Another contrasting feature of this pathway 
is the slower internalization and processing compared to the receptor-mediated CME, with most 
other features being shared [134].  
Figure  6.  Schematic  representation  of  intracellular  processing  of  smaller  liposomal 
nanocarriers (e.g., SUVs). Extracellular SUVs interact  with the cell membrane  and are 
taken up by (A) Clathrin-mediated endocytosis (CME), (B) Caveolin-mediated endocytosis 
(CvME), or (C) Non-clathrin- or non-caveolin-mediated endocytosis (NCME). With CME 
(A) clathrin coated pits form either as a receptor-mediated event or spontaneously, the 
latter  process  called  fluid-phase  endocytosis.  Vesicle  fission  from  the  membrane  is 
mediated  by  the  GTPase dynamin.  Coated vesicles  are internalized, shed their  clathrin 
coats, and develop into early endosomes. With acidification and fusion with enzyme-rich 
pre-lysosomal vesicles in the late endosome stage, a lysosome forms with degradation of 
the ingested materials. In the CvME pathway (B), particles that specifically bind to the cell 
plasma membrane are routed to flask-shaped membrane invaginations that are coated with 
caveolin.  Again,  vesicle  fission  is  dynamin-dependent.  Rather  than  processing  through 
endosomes (dashed arrow), the majority of these vesicles form caveosomes, with further 
processing/routing of the contents based on actions within the endoplasmic reticulum or 
Golgi apparatus. The NCME pathway(s) (C) continue to be investigated. Cholesterol-rich 
membrane microdomains or ―lipid rafts‖, are the specific targets of binding for ligands that 
stimulate this internalization pathway. Similar to CvME, the lysosomal stage is bypassed 
with the sparing of the internalized materials from harsh acidic and enzymatic processing. 
They also appear to be routed to the intracellular membrane organelles. Toxins 2011, 3                                       
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Table 1. Cellular uptake mechanisms for liposomes. 
Mechanisms of 
Endocytosis 
Primary Cell 
Types Involved 
Opsonization 
Dependent 
Surface Feature-
Dependent 
Length of 
Process to 
Processing 
Vesicle 
Size 
Typical Cellular 
Processing 
Other Factors 
Phagocytosis 
Macrophages 
Monocytes 
Neutrophils 
Dendritic cells 
Yes, usually 
Yes, increased for 
both cationic and 
anionic particles 
30 min to 2 h  >250 nm 
Acidified, enzyme-
rich phagolyso-some. 
Increased with 
hydrophobic, rigid, 
non-spherical particles. 
Actin-dependent. 
Macropinocytosis  All cells  No  No  -  1–5 μm  Degradative lysosome  Actin-dependent 
CME and fluid-phase 
endocytosis 
All cells  No 
Enhanced by 
specific ligands 
5–10 min for 
receptor-mediated. 
45–90 min for 
fluid phase. 
<150 nm 
Early and late 
endosomes and 
eventually degradative 
lysosomes 
Receptor-mediated and 
non-specific uptake 
exists. Clathrin- and 
dynamin-dependent. 
CvME 
All cells, but 
especially 
endothelial cells. 
No 
Receptor-ligand 
trafficking on cell 
surface 
20–40 min  <80 nm 
Caveosome, avoiding 
acidic- and enzyme-
rich processing. 
Caveolin- and 
dynamin- dependent 
CME- and CvME- 
independent 
endocytosis 
All cells  No 
Selected by using 
targeting ligands 
specific for 
―rafts‖. 
-  <50 nm 
Non-lysosomal 
pathways 
Still being 
investigated. 
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Caveolin-mediated endocytosis (CvME) features flask-shaped membrane invaginations sized at the 
lower end of the 50–100 nm range [129,130,134,136], lined by the dimeric protein caveolin. Caveolae 
(CvME vesicles) are most abundant in endothelial cells, making up 10–20% of the cell surface [130], 
and  allow  endocytosis  of  various  proteins  and  viruses  (e.g.,  SV40),  as  well  as  smaller  
nanocarriers [122]. CvME is more highly regulated than CME, through the involvement of complex 
signaling on the membrane surface [130,134]. Receptor-ligand interactions on the membrane surface 
traffic  particles  to  caveolar  invaginations  [134].  Caveolar  fission  from  the  membrane  surface  is 
mediated by the GTPase dynamin, a process that is shared with CME [122]. The major differentiation 
between  CME  and  CvME,  besides  the  typical  vesicle  size,  is  the  absence  of  enzymatic  activity 
associated  with  CvME  processing,  allowing  nanocarriers  to  by-pass  the  lysosomal  degradation 
pathways for their payloads (e.g., drugs, peptides, proteins, nucleic acids, etc.). The uptake kinetics are 
not as rapid as seen with CME, but ligands such as albumin, cholesterol, and folic acid are regularly 
taken up using CvME [134]. 
While additional clathrin- and caveolin- independent endocytosis pathways have been described, a 
specific classification for these has only recently been proposed [136]. Like CvME, many, but not all 
of these pathways involve membrane microdomains, or ―rafts‖, that are abundant in cholesterol and 
have  diameters  of  40–50  nm  [130].  Their  specific  mechanisms  and  implications  in  the  uptake  of 
nanocarrier systems remain to be better defined. 
5. Liposomal Toxins 
Distinct  liposome  classes  have  been  developed  to  package  various  therapeutic  agents  for  the 
treatment of cancer, based on structural/pharmacologic features [137]. While most oncologic drugs 
were initially integrated within the aqueous core of SUVs (see Liposome section), drug incorporation 
within  the  liposomal  membranes  of  MLVs  further  expanded  the  repertoire  of  drugs  available  for 
liposomal delivery. Drug loading within liposomes is either a passive (drug is incorporated within the 
vesicle  during  liposome  formation)  or  an  active  (addition  after  vesicle  formation)  process  [138]. 
Hydrophobic drugs (e.g., taxol and annamycin) can be passively incorporated into liposomes, based on 
their  drug-lipid  properties  and  enhanced  by  the  increased  lipid  content  of  MLVs.  Drug  trapping 
efficiencies under these conditions can approach 100% for highly lipid soluble agents. In contrast, 
passive  incorporation  of  hydrophilic  drugs  (e.g.,  topotecan,  irinotecan)  is  primarily  based  on  the 
encapsulated volume of aqueous solution carrying the drug within the vesicle. This internal aqueous 
volume is increased with vesicle size (e.g., LUV) and typically reduced in MLVs (Figures 3 and 4). 
Trapping efficiency under these circumstances is typically <30%, due to the liposome size constraints 
and  drug  solubility  [138],  but  techniques  have  been  developed  to  improve  hydrophilic  drug 
incorporation results approaching those of lipophilic agents [139]. Active drug incorporation methods 
into liposomes have been shown to be strongly affected by the drug-buffer composition used as well as 
the  nature  of  the  membrane  lipid  headgroups  [140].  Remote-loading,  ion-gradient,  intraliposomal 
stabilization methods of hydrophilic drug incorporation within liposomes have proven effective [141]. 
Hydrophobic and hydrophilic chemotherapeutic agents can, therefore, be incorporated into liposomes 
and transported and released over prolonged periods [142–144], compared to the non-encapsulated 
drugs alone. The circulating half-life of these liposomal toxins (LT) can be enhanced further by the Toxins 2011, 3                      
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addition of a polyethylene glycol (PEG) coat to the liposomal surface, which can also be modified with 
specific targeting molecules that increase the specificity for receptor-mediated endocytosis, or other 
cellular incorporation strategies in target cells (see Liposomes, and Cellular Uptake of  Liposomes 
sections above). 
6. CED of Liposomal Toxins: Pre-clinical Neurooncologic Studies 
CED has been used to effectively deliver liposomes and LTs within the CNS in small animals 
with  or  without  tumors  [141,145–149],  canines  with  spontaneous  brain  tumors  [150,151],  and 
nonhuman  primates  [57,58,152].  From  these  studies,  it  has  been  confirmed  that  liposomal 
chemotherapeutics are less toxic and have an extended half-life within brain parenchyma compared 
to  free  drugs  [153].  Relevant  to  this  discussion,  tissue  affinities  for  chemotherapeutic  agents 
delivered via CED were noted to be a limiting factor for parenchymal Vd within the CNS [147], 
despite  being  significantly  greater  than  via  diffusion-based  delivery  methods.  In  this  same  
study  [147],  drug  encapsulation  within liposomes significantly increased the effective Vd  of the 
therapeutic.  Importantly,  alteration  of  liposomal  surface  properties  (e.g.,  presence  or  absence  of 
surface  charge,  percentage  of  PEGylation)  markedly  affected  the  Vd.  Increased  liposomal 
PEGylation yielded the greatest Vd compared to volume of infusion (Vi), probably related to steric 
stabilization and reduced surface charge [147]. Liposomes delivered via CED within the brain were 
noted to preferentially traffic in the ECS along white matter tracts, in a path of least resistance, as 
opposed to passage through more cellular gray matter structures [152,154]. Liposomes were also 
transported  significant  distances  away  from  the  site  of  infusion  upon  gaining  entry  into  the 
perivascular spaces [154], via a perivascular pump mechanism [48]. 
Delivery of LTs via CED in rodents harboring brain tumors confirmed higher concentrations of 
drug at the target site with decreased local toxicity compared to either systemic therapy or CED of 
non-liposomal  drug  [146,148].  Efficacy  of  these  methods  has  been  confirmed  in  rodent  tumor  
models [141,146,148,149], as well as the effective use of mixed liposomes for both drug delivery and 
contrast  agent  visualization  of  the  CED  process  using  RCD  [57,145,155].  In  canines,  similar  
CED-delivered LTs failed to show clinical or histopathological adverse effects in normal [150] or 
brain tumor-bearing animals [151], while confirming clinical efficacy (Figure 2B–D) and highlighting 
the  importance  of  RCD  to  maximize  tumor  coverage  and  minimize  inappropriate  infusions. 
Convection of gadolinium liposomes (GDL) in nonhuman primate brain has confirmed the lack of 
toxicity and ability to monitor the infusion process in a larger brain using RCD methods similar to 
those for humans [58,76]. Recently [156], in vivo CED of magnetic nanospheres conjugated to an 
antibody that selectively binds to the epidermal growth factor receptor (EGFR) mutant (EGFRvIII) 
found on glioblastoma xenografts, not only allowed specific tumor visualization on MRI, but through 
an apoptotic mechanism, was associated with targeted cell death with sparing of normal astrocytes. 
With  these  and  other  preclinical  data  [157],  we  have  argued  for  the  importance  of  a  delivery  
platform  [39]  that  utilizes  RCD  to  monitor  therapeutic  distribution,  and  potential  complications 
associated with CED [62,76] in the neurooncologic patient. 
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7. CED of Liposomal Toxins: Clinical Neurooncologic Studies 
Clinical trials featuring LTs in general oncology have been ongoing for over 20 years [158]. With 
advances in liposomal PEGylation and ligand targeting, improved efficacy and safety for a growing 
number of LTs (e.g., doxorubicin, acridine, Ara-C, daunomycin, retinoid fenretinide, 5-FdU) has been 
confirmed  [159].  Additionally  [160–162],  novel  intraliposomal  drug  loading  and  stabilization 
technologies have allowed incorporation of other therapeutics (e.g., irinotecan, CPT-11), and may lead 
to additional chemotherapeutic agents being available for clinical development as LTs. 
In the brain, use of LTs has been limited over the last decade. PEGylation of some liposomes has 
been  associated  with  complement  activation  with  repeat  injections  [163],  and  the  development  of 
complement activation-related psuedoallergy (CARPA) [164,165], which is potentially life-threatening. 
Initially, liposomes were compared with viral vectors for local direct delivery of genetic payloads to 
tumors.  Although  preclinical  studies  suggested  significant  transduction  rates  using  liposomal  gene 
therapy vectors, they were generally less efficient than viral vectors [166].  
The use of liposomes delivered via CED in clinical neurooncology dates back just over 10 years. In 
an initial phase I/II study [167,168], patients with recurrent glioblastoma multiforme (rGBM) were 
treated with cationic liposomes containing a suicide gene [169,170], sensitizing tumor cells to systemic 
ganciclovir  therapy.  This  trial  reported  no  morbidity  or  mortality  associated  with  the  surgical 
treatment.  Liposomal  delivery  via CED  was felt to cause only  transient clinical  worsening in  the 
patients,  possibly  related  to  the  infused  volume  (30  mL  over  48  h).  Infusion  rates  varied  from  
0.025–1.8 mL/h (maximum of 30 µL/min) and were delivered via infusion pump through either one or 
two  implanted  silicon  catheters  within  the  tumor.  Unfortunately,  although  pre-infusion  CED  of 
gadolinium (Gd) contrast attempted to predict the Vd of the therapeutic infusate, it is not clear as to the 
actual extent of the tumor coverage by the convected therapeutic. The authors actually conclude that 
the beneficial effect in their patients was restricted to a relatively small volume around the infusion  
sites [168], making the Vd of the CED suspect. 
In another phase I/II trial utilizing a similar cationic liposomal vector/CED protocol for progressive 
or rGBM, the gene for human interleukin 12 (IL-12) was delivered in an effort to stimulate a local 
cellular  immune  antitumor  response  [171].  Infusion  flow  rates  in  this  study  ranged  from  0.1  to  
0.5 mL/h (maximum of 8.3 µL/min) until an 11 mL volume was delivered. Although clinical results 
from this trial were not published, the delivery of similar gene products in neurooncology eventually 
shifted  from  initial  use  of  liposomes  to  the  use  of  viral  vectors  with  this  IL-12  paradigm  [172], 
primarily due to the virus’ higher transduction efficiency [98,173]. 
8. Future Directions 
Delivery of LTs bearing additional active agents to tumors within the CNS will be forthcoming, 
based on the significant preclinical experiences to date and the improved methods of incorporation of 
drugs into liposomes. The further development of MRI contrast-bearing liposomal preparations (e.g., 
gadoCED) combined with LTs [155], will allow the use of RCD to better document tumor coverage 
and reduce local complications.  
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Recent  discussion  of  retro-convection  enhanced  delivery  (R-CED)  techniques  [174],  and  their 
ability to augment intravenously delivered therapeutics into brain tumors, may promote a systemically 
administered option for some LTs. A step beyond this concept, yet to be implemented, could include 
the  use  of  both  CED  and  R-CED  to  optimally  perfuse  a  local  tumor  volume  and  susceptible 
surrounding brain, using a modification of the push-pull method of cerebral perfusion [175].  
CED of targeted liposomes carrying a computed tomography (CT) contrast agent for imaging, as 
well as boron (
10B) for use in boron neutron capture therapy (BNCT) is progressing [176], and could 
provide  another  therapeutic  option  for  human  glioma  with  a  real-time  imaging  option.  In  this 
preclinical model [177], transferrin-conjugated PEG liposomes provide selective uptake of 
10B by the 
tumor tissue, thereby increasing tumoricidal activity with BNCT.  
Liposomal  boron  delivery  options  have  been  recently  reviewed  [178],  and  suggest  future 
therapeutic uses of non-targeted and targeted liposomes in BNCT. Finally, the use of focused low 
frequency ultrasound (LFUS) to regulate drug release dynamics from LTs [179], suggests a future 
option for focal parenchymal distribution of liposomally encapsulated therapeutic agents within the Vd 
provided by CED that may be independent of cell binding/processing. Further investigation of the 
relative efficacy/toxicity of this approach versus a targeted liposomal approach will be required. 
9. Summary and Conclusions 
With the tremendous gains in knowledge regarding liposomal chemistry and cellular processing, the 
number  of  therapeutic  agents  available  for  delivery  within  these  nanocarriers  continues  to  grow 
rapidly. Liposomal drug incorporation techniques continue to evolve and provide basic and clinical 
investigators with more potent and selective LTs for use in oncology. CED provides a precise and 
effective method for distribution of LTs within the CNS, bypassing the BBB. Together with liposomal 
contrast agents, LTs convected within a brain tumor and surrounding parenchyma with CED can be 
directly monitored with MRI, improving the ability to cover the proposed target, avoiding significant 
leakage from the target site, and providing improved control and safety.  
It  remains  critical,  however,  for  investigators  and  clinicians  to  understand  the  basics  of  CED 
technology prior to considering its use for human trials. A lack of understanding will not allow the 
proper assessment of this delivery option and prevents a fair comparison to alternatives. Deciphering 
the mechanisms and critical points associated with CED has been painstakingly worked out over the 
last 25 years. At a minimum, investigators should have familiarity with how catheter size and shape 
are essential to minimize tissue trauma and enhance the convection of infusate, while minimizing 
reflux.  Why  flow  rates  are  critical  to  the  CED  process  and  should  typically  not  be  used  above  
5 µL/min in an effort to avoid reflux or focal tissue cavitation. The importance of optimal infusion 
catheter placement within the brain parenchyma, especially related to proximity to ventricular system, 
subarachnoid space, or tumor resection cavity is critical in maximizing effective Vd. Finally, why the 
ability  to  directly  visualize  the  CED  process  with  RCD  is  essential  for  reproducible  treatment 
strategies, improved patient safety, and a better determination of therapeutic efficacy, or lack thereof.  
The  combination  of  CED  and  liposomal  technologies  is  approaching  a  critical  stage  in 
neurooncology,  and  may  finally  affect  the  survival  of  patients  suffering  with  CNS  malignancies  
(Table 2). In this era of evidence-based medicine, real-time imaging has the opportunity to at least Toxins 2011, 3                      
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document that the therapeutic agent has been distributed to the target. Incorporation of agents within 
liposomes for specific intracellular delivery to tumors can reduce the non-specific toxicity of the drug 
and  improve  the  distribution  and  contact  time  within  the  brain  parenchyma.  Controlling  these 
parameters will finally allow a clearer picture of comparative drug efficacy, especially if administered 
via a common platform. 
Table 2. Essential Components for Combined Use of CED and Liposomes in Neurooncology. 
Treatment Modality  Essential Components 
CED  Thorough understanding and implementation of parameters to optimize convection. 
Cannula size and shape 
Infusion flow rates 
Specific infusion volumes 
Safe use of contrast agents (free vs. liposomal) to visualize the CED process (e.g., RCD). 
Avoid reflux or leakage 
Document Vd, and specific coverage of tumor 
Liposomes  Effective use of liposomal technology for improved formulation of LTs. 
Improved understanding of the cellular processing of LTs based on particle size. 
Effective use of lysosomal or non-lysosomal pathways based on delivered  therapeutic agent. 
Better appreciation of ultrasound-induced release dynamics and efficacy. 
Effective tumor-specific targeting based on surface ligands. 
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